 | |
 | |
| Clinical data | |
|---|---|
| Trade names | Palladia |
| AHFS/Drugs.com | Veterinary Use |
| License data | |
| Routes of administration | By mouth |
| Drug class | Antineoplastic agent |
| ATCvet code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 77% |
| Protein binding | 91%-93% |
| Eliminationhalf-life | 16 h |
| Identifiers | |
| |
| CAS Number |
|
| PubChemCID | |
| ChemSpider | |
| UNII |
|
| KEGG | |
| ChEMBL |
|
| PDB ligand | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C22H25FN4O2 |
| Molar mass | 396.466 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Toceranib (INN[2]), sold under the brand namePalladia, is areceptor tyrosine kinase inhibitor that is used in the treatment of caninemast cell tumor also calledmastocytoma.[3] It is the first medication developed specifically for the treatment of cancer in dogs.[4][5] It is used as its phosphate salt, toceranib phosphate. It was developed bySUGEN as SU11654,[6] a sister compound tosunitinib, which was later approved for human therapies. Toceranib is a tyrosine kinase inhibitor and works in two ways: by killing tumor cells and by cutting off the blood supply to the tumor.[4]
The most common side effects include diarrhea, decrease or loss of appetite, lameness, weight loss, and blood in the stool.[4]
Toceranib isindicated to treat canine cutaneous (skin-based) mast cell tumors, a type of cancer responsible for about one out of five cases of canine skin tumors.[4] It is approved to treat the tumors with or without regional lymph node involvement.[4]
This article incorporates text from this source, which is in thepublic domain.
